Oxaliplatin Plus S1 for Treating Sorafenib-Refractory Recurrent Hepatocellular Carcinoma after Liver Transplantation
Jing Suna, Xiaomin Caia, Wei Lia, Meiling Zhanga, Jing Hea, Qian Wanga and Kaihua Lua*
Department of Medical Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
- *Corresponding Author:
- Kaihua Lua
Department of Medical Oncology
the First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
E-mail: [email protected]
Received date: May 06, 2017; Accepted date: June 08, 2017; Published date: June 13, 2017
Citation: Suna J, Caia X, Lia W, Zhanga M, Hea J, et al. (2017) Oxaliplatin Plus S1 for Treating Sorafenib-Refractory Recurrent Hepatocellular Carcinoma after Liver Transplantation. J Carcinog Mutagen 8:296. doi: 10.4172/2157-2518.1000296
Copyright: © 2017 Suna J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recurrent hepatocellular carcinoma (HCC) following liver transplantation (LT) correlates with a poor prognosis due to the lack of effective therapeutic approaches after sorafenib (SORA) or everolimus (EVL) resistance. We assessed the efficacy of SOX (S-1 and oxaplatin) after failed SORA for HCC recurrence after LT based on the results of next generation sequences (NGS). A patient with HCC recurrence after LT was treated with SORA until severe side effect. And then NGS was performed on the primary and metastatic tumor tissues. Investigations on molecular aberrations in cellular pathways and SNPs of drug-related genes were applied. The result of the first NGS shows the benefit from platinum drugs and no abnormalities in PI3K/AKT/mTOR pathway. He received SOX regimen for 4 cycles with progression-free survival (PFS) as long as 4.3 months. NGS of lung and liver metastasis tissues after disease progression still did not match molecular target of everolimus, which he switched to for experimental therapy. He died of failure treatment with 17.3 months overall survival. SOX regimen may benefit recurrent HCC after LT. NGS may provide personalized clinical care for HCC patients.